A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-na&#239;ve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)